IDEAYA BIOSCIENCES INC Share Price Today: Live Updates & Key Insights

IDEAYA BIOSCIENCES INC share price today is $32.75, up 0.46%. The stock opened at $32.6 against the previous close of $32.6, with an intraday high of $33.46 and low of $32.1875.

IDEAYA BIOSCIENCES INC Share Price Chart

IDEAYA BIOSCIENCES INC

us-stock
To Invest in {{usstockname}}
us-stock

IDEAYA BIOSCIENCES INC Share Price Performance

$32.75 0.0046(0.46%) IDYA at 23 Mar 2026 01:34 PM Biotechnology
Lowest Today 32.1875
Highest Today 33.46
Today’s Open 32.6
Prev. Close 32.6
52 Week High 39.28
52 Week Low 13.45
Day’s Range: Low 32.1875 High 33.46
52-Week Range: Low 13.45 High 39.28
1 day return -
1 Week return -5.86
1 month return +2.02
3 month return -7.69
6 month return +26.24
1 year return +76.31
3 year return +137.56
5 year return +41.14
10 year return -

IDEAYA BIOSCIENCES INC Institutional Holdings

FMR Inc 14.97

BlackRock Inc 9.26

HHG PLC 7.32

Fidelity Growth Compy Commingled Pl S 6.74

Capital Research Global Investors 6.01

Vanguard Group Inc 5.72

American Funds SMALLCAP World A 5.46

Federated Hermes Inc 5.27

Fidelity Growth Company Fund 4.73

Point72 Asset Management, L.P. 4.35

Baker Bros Advisors LP 4.12

State Street Corp 3.69

Adage Capital Partners Gp LLC 3.19

Vanguard Total Stock Mkt Idx Inv 3.01

Fiera Capital Corporation 2.78

Logos Global Management LP 2.56

Deerfield Management Co 2.45

State Street® SPDR® S&P® Biotech ETF 2.41

Geode Capital Management, LLC 2.36

Federated Hermes Kaufmann Growth 2.29

Federated Hermes Kaufmann R 2.29

iShares Russell 2000 ETF 2.21

Morgan Stanley - Brokerage Accounts 1.80

Federated Hermes Kaufmann Small Cap A 1.52

Federated Hermes Kaufmann Small Cap Grow 1.52

Fidelity Growth Company K6 1.43

The Goldman Sachs Group Inc 1.40

Fidelity Series Growth Company 1.32

T. Rowe Price Associates, Inc. 1.26

UBS Group AG 1.20

Candriam Luxembourg S.C.A. 1.17

Ensign Peak Advisors Inc 1.11

Vanguard Institutional Extnd Mkt Idx Tr 1.08

Janus Henderson Triton D 0.99

Janus Henderson US SMID Cap Growth 0.99

Fiera Apex SMID Growth Composite 0.95

Fidelity Small Cap Index 0.90

Janus Henderson Global Life Sciences 0.87

Janus Henderson Global Life Sciences D 0.87

iShares Russell 2000 Value ETF 0.78

IDEAYA BIOSCIENCES INC Market Status

Strong Buy: 10

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

IDEAYA BIOSCIENCES INC Fundamentals

Market Cap 2875.91 M

PB Ratio 2.7986

PE Ratio 0.0

Enterprise Value 2251.26 M

Total Assets 1109.32 M

Volume 2403041

IDEAYA BIOSCIENCES INC Company Financials

Annual Revenue FY25:218710000 218.7M, FY24:7000000 7.0M, FY23:23485000 23.5M, FY22:50931000 50.9M, FY21:27941000 27.9M

Annual Profit FY25:214117000 214.1M, FY24:7000000 7.0M, FY23:null 0.0M, FY22:50931000 50.9M, FY21:27941000 27.9M

Annual Net worth FY25:-113698000 -113.7M, FY24:-274477000 -274.5M, FY23:-103207000 -103.2M, FY22:-54808000 -54.8M, FY21:-47531000 -47.5M

Quarterly Revenue Q4/2025:10876000 10.9M, Q3/2025:207834000 207.8M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:7000000 7.0M

Quarterly Profit Q4/2025:9679000 9.7M, Q3/2025:206804000 206.8M, Q2/2025:-1233000 -1.2M, Q1/2025:-1133000 -1.1M, Q4/2024:7000000 7.0M

Quarterly Net worth Q4/2025:-83273000 -83.3M, Q3/2025:119244000 119.2M, Q2/2025:-77491000 -77.5M, Q1/2025:-72178000 -72.2M, Q4/2024:-130312000 -130.3M

About IDEAYA BIOSCIENCES INC & investment objective

Company Information IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer driven by GNAQ/11 mutations, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor that is in a Phase 1 clinical trial for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 dose optimization trial; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 145

Industry Biotechnology

CEO Mr. Yujiro S. Hata

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

IDEAYA BIOSCIENCES INC FAQs

What is the share price of IDEAYA BIOSCIENCES INC today?

The current share price of IDEAYA BIOSCIENCES INC is $32.75.

Can I buy IDEAYA BIOSCIENCES INC shares in India?

Yes, Indian investors can buy IDEAYA BIOSCIENCES INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy IDEAYA BIOSCIENCES INC shares in India?

You can easily invest in IDEAYA BIOSCIENCES INC shares from India by:

Can I buy fractional shares of IDEAYA BIOSCIENCES INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of IDEAYA BIOSCIENCES INC?

IDEAYA BIOSCIENCES INC has a market cap of $2875.91 M.

In which sector does IDEAYA BIOSCIENCES INC belong?

IDEAYA BIOSCIENCES INC operates in the Biotechnology sector.

What documents are required to invest in IDEAYA BIOSCIENCES INC stocks?

To invest, you typically need:

What is the PE and PB ratio of IDEAYA BIOSCIENCES INC?

The PE ratio of IDEAYA BIOSCIENCES INC is N/A and the PB ratio is 2.80.